Meeting
2022 ASCO Annual Meeting
A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer.
Authors
Kristina Hoot Young
Earle A. Chile Research Institute, Providence Cancer Institute, Portland, OR
Kristina Hoot Young , Andrew J Gunderson , Miranda Gilchrist , Mark Whiteford , Maria X Kiely , Amanda Hayman , David P O'Brien , Rehan Ahmad , Jeffrey V Manchio , Evelyn Brosnan , Gina M. Vaccaro , Rui Li , Miklos Simon , Mary McCormick , Ashley Drokin , Julie Cramer , Walter John Urba , Michael Gough , Marka R. Crittenden , Tomoko Yamazaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT02688712
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3617)
DOI
10.1200/JCO.2022.40.16_suppl.3617
Abstract #
3617
Poster Bd #
411
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2023 ASCO Annual Meeting
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.
First Author: Jesse Joshua Smith
Poster
2022 ASCO Annual Meeting
Phase 1b/2 study of a radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemo-radiation in locally advanced or unresectable rectal cancer.
First Author: Ching-Wen Huang
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang